Wie hoch ist der Preis für Sesen Bio, Inc. (SESN)

Preis für Sesen Bio, Inc. (SESN) ist $0.6288

Wie hoch ist die Marktkapitalisierung für Sesen Bio, Inc. (SESN)

Marktkapitalisierung für Sesen Bio, Inc. (SESN) ist $6.00M

Sesen Bio, Inc. (SESN) Operative Marge

Sesen Bio, Inc. is a clinical-stage biotechnology firm deeply involved in the creation, advancement, and eventual market launch of targeted fusion protein therapeutics (TFPTs). Their primary aim is to combat various forms of cancer. Their flagship experimental drug, Vicineum, is a locally administered targeted fusion protein currently undergoing Phase III clinical trials. It targets several conditions, including non-muscle invasive bladder cancer that has not responded to bacillus Calmette-Guérin (BCG) treatment, non-muscle invasive carcinoma in situ of the bladder in patients who previously received BCG, and squamous cell carcinoma affecting the head and neck region. Another promising candidate, VB6-845d, is being developed to address a range of anti-epithelial cell adhesion molecule-positive solid tumors. Sesen Bio is also collaborating with Leiden University Medical Center on the joint development of an imaging agent. Originally incorporated in 2008, the company operated as Eleven Biotherapeutics, Inc. before rebranding as Sesen Bio, Inc. in May 2018. Its corporate headquarters are situated in Cambridge, Massachusetts.

Jahr	Operative Marge	ändert
Nicht genügend Daten für die angegebenen Daten.

Jahr

Operative Marge

ändert

Nicht genügend Daten für die angegebenen Daten.

Unternehmen	Operative Marge	Differenz der operativen Marge	Land
Vertex Pharmaceuticals Incorporated VRTX.US	38.59%	-	US
Argenx SE ARGX.US	28.81%	-	NL
Lonza Group AG LONN.SW	0.00%	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	0.00%	-	KR
UCB S.A. UCB.BR	31.23%	-	BE

Unternehmen

Operative Marge

Differenz der operativen Marge

Land